JOVANA
Library Glossary Getting Started Three Levels Fields How it works Mission
Join the mission
All guides

Keeping Blood Flowing: Antiplatelets and Anticoagulants

Blood is meant to clot when you cut yourself — but a clot inside a heart artery or formed in a fibrillating atrium is dangerous. This guide separates the two families that fight clots: antiplatelets that calm sticky platelets, and anticoagulants that slow the clotting cascade.

Two different clots, two different drugs

Clots come in two flavours, and the body builds them in two different ways. In a fast-flowing artery — like a coronary artery — a clot is mostly platelets sticking together at a torn plaque. In slow, pooling blood — like a fibrillating left atrium or a deep leg vein — a clot is mostly a mesh of fibrin spun by clotting proteins. Different villain, different drug.

Antiplatelet agents target the first kind. Aspirin blunts one of the chemical signals platelets use to clump; clopidogrel blocks a different platelet receptor. After a coronary stent or a heart attack, doctors often use both together for a while — called dual antiplatelet therapy — because a fresh stent is a prime spot for platelets to pile up.

Anticoagulants: slowing the clotting cascade

Anticoagulants target the second kind of clot by slowing the fibrin-making cascade. Warfarin is the classic: it blunts several clotting factors, but its effect drifts with diet and other drugs, so it must be tracked with a blood test, the INR, aiming for a target range. The newer direct oral anticoagulants (DOACs) block a single clotting step, work at a fixed dose, and usually need no routine monitoring — a big practical advantage. Heparin acts within minutes and is given in hospital, often as a bridge while a longer-acting drug takes hold.

The classic reason to anticoagulate is atrial fibrillation: when the atrium quivers instead of contracting, blood stagnates and can form a clot that travels to the brain as a stroke. Anticoagulation hugely lowers that risk. Doctors weigh the stroke risk against bleeding risk before starting — more on that score in a moment.

CHA2DS2-VASc — estimating stroke risk in atrial fibrillation

  C  Congestive heart failure ............ 1
  H  Hypertension ........................ 1
  A2 Age >= 75 .......................... 2
  D  Diabetes ............................ 1
  S2 prior Stroke / TIA / clot ......... 2
  V  Vascular disease (MI, PAD) .......... 1
  A  Age 65-74 ........................... 1
  Sc Sex category (female) .............. 1
  -----------------------------------------
  Worked example: a 78-year-old woman with
  hypertension and diabetes
     Age >=75 .......... 2
     Hypertension ...... 1
     Diabetes .......... 1
     Female ............ 1
     ---------------------
     TOTAL ............. 5  -> high stroke risk

  Higher score = greater yearly stroke risk;
  a score this high strongly favours
  long-term anticoagulation (the bleeding
  risk is weighed separately).
A walk-through of the CHA2DS2-VASc score, which helps decide whether someone with atrial fibrillation should take an anticoagulant.